Search research articles
Contact Us
Filters
Showing results (81-90 of 135) with videos related to
Page
of 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2016
Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study
Peter Fox, Rosemary L Balleine, Clara Lee, et al.
The Prostate
|
March 28, 2024
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer
Kate L Mahon, Sarah Im Sutherland, Hui Ming Lin, et al.
Asia Oceania Journal of Nuclear Medicine & Biology
|
July 12, 2021
Safety and tolerability of Miltuximab<sup>®</sup> - a first in human study in patients with advanced solid cancers
Dhanusha Sabanathan, Douglas H Campbell, Vicki M Velonas, et al.
Cancers
|
October 14, 2022
Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin
Blossom Mak, Hui-Ming Lin, Thy Duong, et al.
Breast (Edinburgh, Scotland)
|
November 8, 2020
Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
Clara Inkyung Lee, Siew Kee Low, Ricardo Maldonado, et al.
BMJ Open
|
March 3, 2021
High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial
Visalini Nair-Shalliker, David P Smith, Val Gebski, et al.
British Journal of Cancer
|
September 11, 2018
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
Thomas Powles, Robert J Motzer, Bernard Escudier, et al.
International Journal of Cancer
|
July 26, 2017
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer
Hui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, et al.
The Lancet. Oncology
|
July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Laurence Albiges, Howard Gurney, Vagif Atduev, et al.
Clinical Pharmacokinetics
|
November 16, 2013
Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study
Jacqueline S L Kloth, Heinz-Josef Klümpen, Huixin Yu, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 135) with videos related to
Sort By:
Page
of 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2016
Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study
Peter Fox, Rosemary L Balleine, Clara Lee, et al.
The Prostate
|
March 28, 2024
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer
Kate L Mahon, Sarah Im Sutherland, Hui Ming Lin, et al.
Asia Oceania Journal of Nuclear Medicine & Biology
|
July 12, 2021
Safety and tolerability of Miltuximab<sup>®</sup> - a first in human study in patients with advanced solid cancers
Dhanusha Sabanathan, Douglas H Campbell, Vicki M Velonas, et al.
Cancers
|
October 14, 2022
Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin
Blossom Mak, Hui-Ming Lin, Thy Duong, et al.
Breast (Edinburgh, Scotland)
|
November 8, 2020
Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
Clara Inkyung Lee, Siew Kee Low, Ricardo Maldonado, et al.
BMJ Open
|
March 3, 2021
High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial
Visalini Nair-Shalliker, David P Smith, Val Gebski, et al.
British Journal of Cancer
|
September 11, 2018
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
Thomas Powles, Robert J Motzer, Bernard Escudier, et al.
International Journal of Cancer
|
July 26, 2017
A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer
Hui-Ming Lin, Kate L Mahon, Jacquelyn M Weir, et al.
The Lancet. Oncology
|
July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Laurence Albiges, Howard Gurney, Vagif Atduev, et al.
Clinical Pharmacokinetics
|
November 16, 2013
Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study
Jacqueline S L Kloth, Heinz-Josef Klümpen, Huixin Yu, et al.
Page
of 14